Baltic Countries

Gene Summit in the Year of the Helix

23.11.2003

In mid-September more than 450 top scientists from genetics and biotechnology as well as representatives of biotech companies attended the two-day international Gene Forum 2003 held in the Vanemuine Conference Hall in Tartu. All participants assured that the constant improvement of the knowledge about the genetic background of humans enables to fight diseases more effectively.

“We have to understand genetics to fight human diseases.” This appeal was the quintessence of the 4th International Congress “Gene Forum 2003” which was held from September 12-13 in the Estonian city of Tartu. “At least one fifth of the participants were from abroad”, said Prof. Andres Metspalu, head of the Scientific Programme Committee of the Forum.
This year's event was subtitled “50 Years of Double Helix” in commemoration of the elucidation of DNA's molecular structure by Francis Crick and James Watson 50 years ago. Additionally, Watson's “The Double Helix” translation into Estonian was published and presented at the forum. Sort of late, one may sarcastically add, since the original version was published back in 1968, but given that Estonia is driving it's well known Genome Project forward with high-speed (see also page 20) the baltic scientists assured, they have understood the genetic topics very well.
Organized by the Estonian Genome Foundation some 25 speakers discussed the new possibilities of genetics and biotechnology that have been developed during the past 50 years. As keynote speaker Prof. Rolf Zinkernagel, Institute of Experimental Immunology, University of Zurich, and 1996 Nobel Laureate in Medicine for discoveries concerning the specificity of the cell-mediated immune defence, introduced the mechanisms of immunological memory and the possibilities of working out new vaccines.
A special session on biobanks included the lectures of the representatives of the Estonian Genome Project Foundation, Iceland's Gene Bank as well as the UK Biobank Project. Dr John Newton, Chief Executive Officer of the UK Biobank Project, recognized the success of the Estonian project and emphasized that today there is a common understanding in the world about the need to establish biobanks.
In a session dedicated to pharmacogenetics Prof. Hannu Raunio, University of Kuopio, Finland, and Prof. Magnus Ingelman-Sundberg, Karolinska Institute, Stockholm - amongst others - gave an overview on the expectations of pharmaceutical industry related to the development of genetics. According to estimates, only some 30% of patients respond adequately to drug treatment and about 10% may experience adverse side effects. Representing the German biotechnology company febit AG, Markus Beier, Director of Application Development, introduced the microarray plattform “geniom one”. Febit claims that the system helps to manage the large amounts of data hand-in-hand with the sequence analysis in genome projects.
As the winner of the second Biotechnology Award, established last year by PricewaterhouseCoopers and the Estonian Genome Foundation, Quattromed Ltd., was awarded with Euro3.500. The spin-off company of the University of Tartu submitted a project that dealt with recombinant viruses and cell lines.

Baltic Countries

17.08.2011

Under the motto “10 Years ScanBalt Bioregion – Towards a Balanced Regional Development and Smart Specialisation in the Baltic Sea Region”, the ScanBalt Bio­Region is holding the 10th ScanBalt Forum from September 21st-23rd....

Baltic Countries

11.06.2011

Kaunas – US-based Valeant Pharmaceuticals International Inc. said in mid-May that it is purchasing an 87.2% share in Lithuanian generic drug maker Sanitas AB for EUR314m in cash, and will make a mandatory tender offer to acquire...

Baltic Countries

25.05.2011

Kaunas – US company Valeant Pharmaceuticals International, Inc. wants to purchase Lithuanian generic drug maker Sanitas AB for EUR314 million in cash. Shareholders of Sanitas have already agreed to sell Valeant 87.2% of Sanitas’...

Baltic Countries

03.11.2010

Bucharest – Plans by Romanian Environment Minister Lazlo Borbely to implement a five-year ban on GMO acreage beginning next spring have been fiercely attacked by the country’s Agriculture Minister Valeriu Tabara. Borbely has...

Baltic Countries

16.09.2010

Kopavogur – Iceland’s ORF Genetics Ltd. and the Indian company DM Corp. Pvt. Ltd. are planning to collaborate on the development, production and marketing of protein drugs. The two CEOs Björn Örvar (ORF) and Dilip Mohite (DM...

Baltic Countries

12.09.2010

Vilnius/Waltham – Lab giant Thermo Fisher Scientific has completed its EUR212m cash takeover of Lithuania‘s largest lab tools provider Fermentas Inter­na­tional. Integration of the firm into Thermo Fisher’s Analytical...

Baltic Countries

08.09.2010

Riga – According to an announcement following a meeting of senior staff in mid-August, JCS Grindeks will collaborate in product development with the Latvian Institute of Organic Synthesis (IOS). The collaboration will involve the...

Baltic Countries

09.07.2010

Riga – Latvian pharma manufacturing firm Grindeks has announced it will significantly increase revenues to EUR13.5m this year. Issued in mid-June, the prognosis was based on good sales in eastern European markets in the first...

Baltic Countries

02.07.2010

Vilnius/Waltham – The life sciences tools market is slowly being whittled down to a few major players. At the end of May, Lithuania’s largest lab supplier was the most recent target of an acquisition, when US lab giant Thermo...

Displaying results 1 to 10 out of 58

1-10 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/news/messages-archive/archive-baltic-countries/article/gene-summit-in-the-year-of-the-helix.html

Events

All Events

Stock list

All quotes

TOP

  • NOVACYT (F)4.98 EUR5.96%
  • STALLERGENES (F)53.50 EUR4.37%
  • MORPHOSYS (D)72.25 EUR3.96%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • OREXO (S)137.00 SEK-5.35%

TOP

  • WILEX (D)3.10 EUR307.9%
  • SANTHERA (CH)67.95 CHF88.7%
  • ADDEX (CH)4.03 CHF79.9%

FLOP

  • MERCK KGAA (D)64.38 EUR-49.4%
  • HYBRIGENICS (F)1.77 EUR-27.5%
  • CHRONTECH PHARMA (S)0.07 SEK-22.2%

TOP

  • SANTHERA (CH)67.95 CHF3457.6%
  • GW PHARMACEUTICALS (UK)419.75 GBP715.0%
  • PAION (D)2.77 EUR313.4%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-91.8%
  • THROMBOGENICS (B)9.54 EUR-69.5%

No liability assumed, Date: 27.07.2014

Job Advert

Executive Director of the IMI Joint Undertaking

The Innovative Medicines Initiative Joint Undertaking (IMI JU) is a public-private partnership between the European Commission and the European Federation of Pharmaceutical Industries Associations (EFPIA).
The Executive Director will lead and manage the Joint Undertaking and take overall responsibility for its operations ensuring the achievement of the Joint Undertaking's objectives. more...


Current issue

All issues

Product of the week

Products